Search

Your search keyword '"Rebuzzi, Sara Elena"' showing total 322 results
Start Over Author "Rebuzzi, Sara Elena"
322 results on '"Rebuzzi, Sara Elena"'

1. Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study

Author

Fiala, Ondřej, Massari, Francesco, Basso, Umberto, Giannatempo, Patrizia, Grande, Enrique, Buti, Sebastiano, Myint, Zin W., De Giorgi, Ugo, Pichler, Renate, Grillone, Francesco, Ürün, Yüksel, Calabrò, Fabio, Bourlon, Maria T., Galli, Luca, Kanesvaran, Ravindran, Roviello, Giandomenico, Kucharz, Jakub, Rizzo, Mimma, Park, Se Hoon, Cerbone, Linda, Seront, Emmanuel, Messina, Carlo, Molina-Cerrillo, Javier, Santini, Daniele, Yano, Akihiro, Incorvaia, Lorena, Catalano, Martina, Pinto, Alvaro, Formisano, Luigi, Soares, Andrey, Facchini, Gaetano, Fornarini, Giuseppe, Poprach, Alexandr, Rebuzzi, Sara Elena, Nasso, Cecilia, Spinelli, Gian Paolo, Angel, Martin, Stellato, Marco, Tural, Deniz, Aurilio, Gaetano, Epstein, Ilana, Carrozza, Francesco, Monteiro, Fernando Sabino Marques, Benedetti, Giovanni, Büchler, Tomáš, Ortega, Cinzia, Zakopoulou, Roubini, Battelli, Nicola, Porta, Camillo, Bellmunt, Joaquin, Gupta, Shilpa, and Santoni, Matteo

Published
2024
Full Text
View/download PDF

2. Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study

Author

Messina, Carlo, Catalano, Martina, Roviello, Giandomenico, Gandini, Annalice, Maruzzo, Marco, De Giorgi, Ugo, Pedrazzoli, Paolo, Sbrana, Andrea, Zucal, Paolo Andrea, Masini, Cristina, Naglieri, Emanuele, Procopio, Giuseppe, Milella, Michele, Catalano, Fabio, Fratino, Lucia, Pipitone, Stefania, Ricotta, Riccardo, Panni, Stefano, Mollica, Veronica, Soraru, Mariella, Prati, Veronica, Atzori, Francesco, Di Napoli, Marilena, Messina, Marco, Morelli, Franco, Prati, Giuseppe, Nole, Franco, Malgeri, Andrea, Tudini, Marianna, Vignani, Francesca, Cavo, Alessia, Signori, Alessio, Banna, Giuseppe Luigi, Rescigno, Pasquale, Buti, Sebastiano, Rebuzzi, Sara Elena, and Fornarini, Giuseppe

Published
2024
Full Text
View/download PDF

4. Instrumental activities of daily living in older patients with metastatic prostate cancer: results from the meet-URO network ADHERE prospective study

Author

Fratino, Lucia, Polesel, Jerry, Giunta, Emilio Francesco, Maruzzo, Marco, Buti, Sebastiano, Hassan, Mona Ali, Basso, Umberto, Rebuzzi, Sara Elena, De Giorgi, Ugo, Cinausero, Marika, Lipari, Helga, Gamba, Teresa, Bimbatti, Davide, Dri, Arianna, Ermacora, Paola, Vignani, Francesca, Fornarini, Giuseppe, Rescigno, Pasquale, and Banna, Giuseppe Luigi

Published
2024
Full Text
View/download PDF

5. External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations

Author

Maffezzoli, Michele, Santoni, Matteo, Mazzaschi, Giulia, Rodella, Sara, Lai, Eleonora, Maruzzo, Marco, Basso, Umberto, Bimbatti, Davide, Iacovelli, Roberto, Anghelone, Annunziato, Fiala, Ondřej, Rebuzzi, Sara Elena, Fornarini, Giuseppe, Lolli, Cristian, Massari, Francesco, Rosellini, Matteo, Mollica, Veronica, Nasso, Cecilia, Acunzo, Alessandro, Silini, Enrico Maria, Quaini, Federico, De Filippo, Massimo, Brunelli, Matteo, Banna, Giuseppe L., Rescigno, Pasquale, Signori, Alessio, and Buti, Sebastiano

Published
2024
Full Text
View/download PDF

6. Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal Cancer

Author

Del Re, Marzia, Crucitta, Stefania, Brighi, Nicole, Kinspergher, Stefania, Mercinelli, Chiara, Rizzo, Mimma, Conteduca, Vincenza, Rebuzzi, Sara Elena, Beninato, Teresa, Venturi, Giulia, Doni, Laura, Verzoni, Elena, Puglisi, Silvia, Landriscina, Matteo, Porta, Camillo, Manfredi, Fiorella, Caffo, Orazio, De Giorgi, Ugo, Fogli, Stefano, and Danesi, Romano

Published
2024
Full Text
View/download PDF

7. Efficacy and Safety of Pembrolizumab plus Axitinib combination for Metastatic Renal Cell Carcinoma in a Real-World Scenario: Data From the Prospective ProPAXI Study

Author

Guida, Annalisa, Gili, Alessio, Mosillo, Claudia, Maruzzo, Marco, Lai, Eleonora, Pierantoni, Francesco, Bimbatti, Davide, Basso, Umberto, Fornarini, Giuseppe, Rebuzzi, Sara Elena, Calabrò, Fabio, Cerbone, Linda, Caserta, Claudia, Sirgiovanni, Grazia, Serafin, Debora, Caffo, Orazio, Scagliarini, Sarah, and Bracarda, Sergio

Published
2024
Full Text
View/download PDF

8. Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25)

Author

Gambale, Elisabetta, Maruzzo, Marco, Messina, Carlo, De Gennaro Aquino, Irene, Vascotto, Ismaela Anna, Rossi, Virginia, Bimbatti, Davide, Cavasin, Nicolò, Messina, Marco, Mennitto, Alessia, Rebuzzi, Sara Elena, Nasso, Cecilia, Mercinelli, Chiara, Maiorano, Brigida Anna, Fanelli, Martina, Sorarù, Mariella, Scolari, Federico, Mela, Marinella Micol, Galli, Luca, Salfi, Alessia, Rizzo, Mimma, Puglisi, Silvia, Orlando, Valentina, Fornarini, Giuseppe, Rametta, Alessandro, Giannatempo, Patrizia, Cerbone, Linda, Doni, Laura, Roviello, Giandomenico, Pillozzi, Serena, and Antonuzzo, Lorenzo

Published
2024
Full Text
View/download PDF

9. Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27

Author

Stellato, Marco, Buti, Sebastiano, Maruzzo, Marco, Bassanelli, Maria, Bersanelli, Melissa, Napoli, Marilena Di, Dionese, Michele, Fanelli, Martina, Filippi, Roberto, Fotia, Giuseppe, Galli, Luca, Grillone, Francesco, Maffezzoli, Michele, Maiorano, Brigida Anna, Nasso, Cecilia, Rebuzzi, Sara Elena, Lalli, Luca, Roviello, Giandomenico, Sorarù, Mariella, Vincenzi, Bruno, Procopio, Giuseppe, and Verzoni, Elena

Published
2024
Full Text
View/download PDF

10. Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study

Author

Santoni, Matteo, Massari, Francesco, Myint, Zin W., Iacovelli, Roberto, Pichler, Martin, Basso, Umberto, Kopecky, Jindrich, Kucharz, Jakub, Buti, Sebastiano, Rizzo, Mimma, Galli, Luca, Büttner, Thomas, De Giorgi, Ugo, Kanesvaran, Ravindran, Fiala, Ondřej, Grande, Enrique, Zucali, Paolo Andrea, Fornarini, Giuseppe, Bourlon, Maria T., Scagliarini, Sarah, Molina-Cerrillo, Javier, Aurilio, Gaetano, Matrana, Marc R., Pichler, Renate, Cattrini, Carlo, Büchler, Tomas, Seront, Emmanuel, Calabrò, Fabio, Pinto, Alvaro, Berardi, Rossana, Zgura, Anca, Mammone, Giulia, Ansari, Jawaher, Atzori, Francesco, Chiari, Rita, Bamias, Aristotelis, Caffo, Orazio, Procopio, Giuseppe, Bassanelli, Maria, Merler, Sara, Messina, Carlo, Küronya, Zsófia, Mosca, Alessandra, Bhuva, Dipen, Vau, Nuno, Incorvaia, Lorena, Rebuzzi, Sara Elena, Roviello, Giandomenico, Zabalza, Ignacio Ortego, Rizzo, Alessandro, Mollica, Veronica, Sorgentoni, Giulia, Monteiro, Fernando Sabino M., Montironi, Rodolfo, Battelli, Nicola, and Porta, Camillo

Published
2023
Full Text
View/download PDF

12. Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9)

Author

Damassi, Alessandra, Cremante, Malvina, Signori, Alessio, Rebuzzi, Sara Elena, Fornarini, Giuseppe, Giudice, Giulia Claire, Maruzzo, Marco, Procopio, Giuseppe, Sorarù, Mariella, Di Napoli, Marilena, Fratino, Lucia, Santini, Daniele, Grillone, Francesco, Ballestrin, Melissa, Dionese, Michele, Nasso, Cecilia, Catalano, Fabio, Murianni, Veronica, Rescigno, Pasquale, Anpalakhan, Shobana, Banna, Giuseppe Luigi, Basso, Umberto, and Buti, Sebastiano

Published
2024
Full Text
View/download PDF

13. Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?

Author

Santoni, Matteo, Buti, Sebastiano, Myint, Zin W., Maruzzo, Marco, Iacovelli, Roberto, Pichler, Martin, Kopecky, Jindrich, Kucharz, Jakub, Rizzo, Mimma, Galli, Luca, Büttner, Thomas, De Giorgi, Ugo, Kanesvaran, Ravindran, Fiala, Ondřej, Grande, Enrique, Zucali, Paolo Andrea, Kopp, Ray Manneh, Fornarini, Giuseppe, Bourlon, Maria T., Scagliarini, Sarah, Molina-Cerrillo, Javier, Aurilio, Gaetano, Matrana, Marc R., Pichler, Renate, Cattrini, Carlo, Büchler, Tomas, Massari, Francesco, Seront, Emmanuel, Calabrò, Fabio, Pinto, Alvaro, Berardi, Rossana, Zgura, Anca, Mammone, Giulia, Ansari, Jawaher, Atzori, Francesco, Chiari, Rita, Bamias, Aristotelis, Caffo, Orazio, Procopio, Giuseppe, Sunela, Kaisa, Bassanelli, Maria, Ortega, Cinzia, Grillone, Francesco, Landmesser, Johannes, Milella, Michele, Messina, Carlo, Küronya, Zsófia, Mosca, Alessandra, Bhuva, Dipen, Santini, Daniele, Vau, Nuno, Morelli, Franco, Incorvaia, Lorena, Rebuzzi, Sara Elena, Roviello, Giandomenico, Soares, Andrey, Bisonni, Renato, Bimbatti, Davide, Zabalza, Ignacio Ortego, Rizzo, Alessandro, Mollica, Veronica, Sorgentoni, Giulia, Monteiro, Fernando Sabino M., Battelli, Nicola, Bracarda, Sergio, and Porta, Camillo

Published
2024
Full Text
View/download PDF

14. Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis

Author

Anpalakhan, Shobana, Signori, Alessio, Cortellini, Alessio, Verzoni, Elena, Giusti, Raffaele, Aprile, Giuseppe, Ermacora, Paola, Catino, Annamaria, Pipitone, Stefania, Di Napoli, Marilena, Scotti, Vieri, Mazzoni, Francesca, Guglielmini, Pamela F., Veccia, Antonello, Maruzzo, Marco, Schinzari, Giovanni, Casadei, Chiara, Grossi, Francesco, Rizzo, Mimma, Montesarchio, Vincenzo, Verderame, Francesco, Mencoboni, Manlio, Zustovich, Fable, Fratino, Lucia, Accettura, Caterina, Cinieri, Saverio, Tondini, Carlo Alberto, Camerini, Andrea, Banzi, Maria Chiara, Sorarù, Mariella, Zucali, Paolo Andrea, Vignani, Francesca, Ricciardi, Serena, Russo, Antonio, Cosenza, Agnese, Di Maio, Massimo, De Giorgi, Ugo, Pignata, Sandro, Giannarelli, Diana, Pinto, Carmine, Buti, Sebastiano, Fornarini, Giuseppe, Rebuzzi, Sara Elena, Rescigno, Pasquale, Addeo, Alfredo, Banna, Giuseppe L., and Bersanelli, Melissa

Published
2023
Full Text
View/download PDF

16. The role of the caregiver in older patients with advanced prostate cancer: results from the ADHERE Prospective Study of the Meet-URO network

Author

Giunta, Emilio Francesco, De Padova, Silvia, Anpalakhan, Shobana, De Giorgi, Ugo, Maruzzo, Marco, Rebuzzi, Sara Elena, Cinausero, Marika, Fratino, Lucia, Lipari, Helga, Gamba, Teresa, Bimbatti, Davide, Dri, Arianna, Ermacora, Paola, Vignani, Francesca, Basso, Umberto, Buti, Sebastiano, Gandini, Annalice, Cremante, Malvina, Fornarini, Giuseppe, Rescigno, Pasquale, and Banna, Giuseppe Luigi

Published
2023
Full Text
View/download PDF

18. Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223

Author

Bauckneht, Matteo, Lai, Rita, D’Amico, Francesca, Miceli, Alberto, Donegani, Maria Isabella, Campi, Cristina, Schenone, Daniela, Raffa, Stefano, Chiola, Silvia, Lanfranchi, Francesco, Rebuzzi, Sara Elena, Zanardi, Elisa, Cremante, Malvina, Marini, Cecilia, Fornarini, Giuseppe, Morbelli, Silvia, Piana, Michele, and Sambuceti, Gianmario

Published
2022
Full Text
View/download PDF

19. The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study

Author

Rebuzzi, Sara Elena, Signori, Alessio, Banna, Giuseppe Luigi, Gandini, Annalice, Fornarini, Giuseppe, Damassi, Alessandra, Maruzzo, Marco, De Giorgi, Ugo, Basso, Umberto, Chiellino, Silvia, Galli, Luca, Zucali, Paolo Andrea, Fantinel, Emanuela, Naglieri, Emanuele, Procopio, Giuseppe, Milella, Michele, Boccardo, Francesco, Fratino, Lucia, Pipitone, Stefania, Ricotta, Riccardo, Panni, Stefano, Mollica, Veronica, Sorarù, Mariella, Santoni, Matteo, Cortellini, Alessio, Prati, Veronica, Soto Parra, Hector Josè, Santini, Daniele, Atzori, Francesco, Di Napoli, Marilena, Caffo, Orazio, Messina, Marco, Morelli, Franco, Prati, Giuseppe, Nolè, Franco, Vignani, Francesca, Cavo, Alessia, Roviello, Giandomenico, Rescigno, Pasquale, and Buti, Sebastiano

Published
2022
Full Text
View/download PDF

21. The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study)

Author

Bauckneht, Matteo, Rebuzzi, Sara Elena, Signori, Alessio, Frantellizzi, Viviana, Murianni, Veronica, Lodi Rizzini, Elisa, Mascia, Manlio, Lavelli, Valentina, Donegani, Maria Isabella, Ponzano, Marta, Gaudiano, Angela, Stazza, Maria Lina, Licari, Maria, Cavallini, Letizia, Laghi, Viola, Cindolo, Luca, Maggi, Martina, Sciarra, Alessandro, Mammucci, Paolo, Sambuceti, Gianmario, Costa, Renato Patrizio, Spanu, Angela, Rubini, Giuseppe, Monari, Fabio, De Vincentis, Giuseppe, and Fornarini, Giuseppe

Published
2022
Full Text
View/download PDF

23. Hyperthyroidism in non-seminomatous testicular germ cell tumors: two case reports and literature review

Author

Favero, Diletta, primary, Oing, Christoph, additional, Seidel, Christoph, additional, Rescigno, Pasquale, additional, Catalano, Fabio, additional, Cremante, Malvina, additional, Rebuzzi, Sara Elena, additional, Gatto, Federico, additional, Rosti, Giovanni, additional, Ferone, Diego, additional, Fornarini, Giuseppe, additional, and Cocchiara, Francesco, additional

Published
2024
Full Text
View/download PDF

24. Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)

Author

Santoni, Matteo, Massari, Francesco, Myint, Zin W., Iacovelli, Roberto, Pichler, Martin, Basso, Umberto, Kopecky, Jindrich, Kucharz, Jakub, Buti, Sebastiano, Salfi, Alessia, Büttner, Thomas, De Giorgi, Ugo, Kanesvaran, Ravindran, Fiala, Ondřej, Grande, Enrique, Zucali, Paolo Andrea, Fornarini, Giuseppe, Bourlon, Maria T, Scagliarini, Sarah, Molina-Cerrillo, Javier, Aurilio, Gaetano, Matrana, Marc R, Pichler, Renate, Cattrini, Carlo, Büchler, Tomas, Seront, Emmanuel, Calabrò, Fabio, Pinto, Alvaro, Berardi, Rossana, Zgura, Anca, Mammone, Giulia, Ansari, Jawaher, Atzori, Francesco, Chiari, Rita, Zakopoulou, Roubini, Caffo, Orazio, Procopio, Giuseppe, Bassanelli, Maria, Zampiva, Ilaria, Messina, Carlo, Küronya, Zsófia, Mosca, Alessandra, Bhuva, Dipen, Vau, Nuno, Incorvaia, Lorena, Rebuzzi, Sara Elena, Roviello, Giandomenico, Zabalza, Ignacio Ortego, Rizzo, Alessandro, Mollica, Veronica, Catalini, Ilaria, Monteiro, Fernando Sabino M., Montironi, Rodolfo, Battelli, Nicola, Rizzo, Mimma, and Porta, Camillo

Published
2023
Full Text
View/download PDF

25. Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study.

Author

Catalano, Martina, Rebuzzi, Sara Elena, Maruzzo, Marco, De Giorgi, Ugo, Buti, Sebastiano, Galli, Luca, Fornarini, Giuseppe, Zucali, Paolo Andrea, Claps, Melanie, Chiellino, Silvia, Zampiva, Ilaria, Pipitone, Stefania, Ricotta, Riccardo, Sorarù, Mariella, Mollica, Veronica, Tudini, Marianna, Fratino, Lucia, Prati, Veronica, Caffo, Orazio, and Atzori, Francesco

Subjects
TREATMENT effectiveness, BONE metastasis, SODIUM, IMMUNE checkpoint inhibitors, RENAL cell carcinoma, HYPERNATREMIA
Abstract

Background: Immune-checkpoint inhibitors (ICIs) have significantly improved metastatic renal cell carcinoma (mRCC) prognosis, although their efficacy in patients with bone metastases (BMs) remains poorly understood. We investigated the prognostic role of natremia in pretreated RCC patients with BMs receiving immunotherapy. Materials and Methods: This retrospective multicenter study included RCC patients with BMs receiving nivolumab as second-line therapy or beyond. Inclusion criteria involved baseline sodium levels (pre-ICI) and sodium levels after 4 weeks of nivolumab initiation (post-ICI). The population was divided into two groups based on the median value, and response rates, progression-free survival (PFS), and overall survival (OS) were assessed. Results: Among 120 eligible patients, those with pre-treatment sodium levels =140 mEq/L showed longer OS (18.7 vs. 12.0 months, p=0.04). Pre-treatment sodium levels =140 mEq/L were associated with better OS compared to levels <140 mE/L (18.7 vs. 12.0, p=0.04). Post-treatment sodium levels =140mEq/L were associated with improved PFS (9.6 vs. 3.2 months) and OS (25.1 vs. 8.8 months) (p=0.05 and p<0.01, respectively). Patients with consistent sodium levels =140 mEq/L at both time points exhibited the best outcomes compared to those with lower values (PFS 11.5 vs. 3.3 months and OS 42.2 vs. 9.0 months, respectively, p<0.01). Disease control rate was significantly higher in the latter group (p<0.01). Multivariate analysis confirmed the prognostic significance of sodium levels. Conclusion: Elevated sodium levels (=140 mEq/L) pre- and post-ICI treatment correlate with better survival outcomes in mRCC patients with BMs. This finding suggests sodium level assessment as a potential prognostic factor in these patients and warrants further investigation, particularly in combination immunotherapy settings. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non–Small-cell Lung Cancer Treated With Immunotherapy

Author

Prelaj, Arsela, Rebuzzi, Sara Elena, Pizzutilo, Pamela, Bilancia, Massimo, Montrone, Michele, Pesola, Francesco, Longo, Vito, Del Bene, Gabriella, Lapadula, Vittoria, Cassano, Flavio, Petrillo, Patrizia, Bafunno, Daniela, Varesano, Niccolò, Lamorgese, Vito, Mastrandrea, Angelica, Ricci, Donatella, Catino, Annamaria, and Galetta, Domenico

Published
2020
Full Text
View/download PDF

28. Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of Meet-URO15 study

Author

Messina, Carlo, primary, Catalano, Martina, additional, roviello, giandomenico, additional, Gandini, Annalice, additional, Maruzzo, Marzo, additional, De Giorgi, Ugo, additional, Pedrazzoli, Paolo, additional, Sbrana, Andrea, additional, Zucali, Paolo Ansrea, additional, Masini, Cristina, additional, Naglieri, Emanuele, additional, Procopio, Giuseppe, additional, Milella, Michele, additional, Catalano, Fabio, additional, Fratino, Lucia, additional, Pipitone, Stefania, additional, Ricotta, Riccardo, additional, Panni, Stefano, additional, Mollica, Veronica, additional, Atzori, Francesco, additional, Napoli, Marilena Di, additional, Messina, Marco, additional, Morelli, Franco, additional, Prati, Giuseppe, additional, Nolè, Franco, additional, Malgeri, Andrea, additional, Tudini, Marianna, additional, Vignani, Francesca, additional, Cavo, Alessia, additional, Signori, Alessio, additional, Banna, Giuseppe Luigi, additional, Rescigno, Pasquale, additional, Buti, Stefano, additional, Rebuzzi, Sara Elena, additional, and Fornarini, Giuseppe, additional

Published
2024
Full Text
View/download PDF

30. Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab

Author

Catalano, Martina, primary, Rebuzzi, Sara Elena, additional, Maruzzo, Marco, additional, De Giorgi, Ugo, additional, Buti, Sebastiano, additional, Galli, Luca, additional, Fornarini, Giuseppe, additional, Zucali, Paolo Andrea, additional, Procopio, Giuseppe, additional, Chiellino, Silvia, additional, Milella, Michele, additional, Catalano, Fabio, additional, Pipitone, Stefania, additional, Ricotta, Riccardo, additional, Sorarù, Mariella, additional, Mollica, Veronica, additional, Tudini, Marianna, additional, Fratino, Lucia, additional, Prati, Veronica, additional, Caffo, Orazio, additional, Atzori, Francesco, additional, Morelli, Franco, additional, Prati, Giuseppe, additional, Nolè, Franco, additional, Vignani, Francesca, additional, Cavo, Alessia, additional, Di Napoli, Marilena, additional, Malgeri, Andrea, additional, Naglieri, Emanuele, additional, Signori, Alessio, additional, Banna, Giuseppe Luigi, additional, Rescigno, Pasquale, additional, Antonuzzo, Lorenzo, additional, and Roviello, Giandomenico, additional

Published
2023
Full Text
View/download PDF

31. International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma – Meet-URO 33 study (REGAL study)

Author

Rebuzzi, Sara Elena, primary, Fornarini, Giuseppe, additional, Signori, Alessio, additional, Buti, Sebastiano, additional, Procopio, Giuseppe, additional, De Giorgi, Ugo, additional, Pignata, Sandro, additional, Naglieri, Emanuele, additional, Maruzzo, Marco, additional, Banna, Giuseppe Luigi, additional, Rescigno, Pasquale, additional, Messina, Carlo, additional, Mattana, Alvise, additional, Basso, Umberto, additional, and Bimbatti, Davide, additional

Published
2023
Full Text
View/download PDF

32. External Validation of a Red Cell-based Blood Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Treated With First- Line Immunotherapy Combinations

Author

MAFFEZZOLI, Michele, primary, SANTONI, Matteo, additional, MAZZASCHI, Giulia, additional, RODELLA, Sara, additional, LAI, Eleonora, additional, MARUZZO, Marco, additional, BASSO, Umberto, additional, BIMBATTI, Davide, additional, IACOVELLI, Roberto, additional, ANGHELONE, Annunziato, additional, FIALA, Ondřej, additional, REBUZZI, Sara Elena, additional, FORNARINI, Giuseppe, additional, LOLLI, Cristian, additional, MASSARI, Francesco, additional, ROSELLINI, Matteo, additional, MOLLICA, Veronica, additional, NASSO, Cecilia, additional, ACUNZO, Alessandro, additional, SILINI, Enrico Maria, additional, QUAINI, Federico, additional, DE FILIPPO, Massimo, additional, BRUNELLI, Matteo, additional, BANNA, Giuseppe L., additional, RESCIGNO, Pasquale, additional, SIGNORI, Alessio, additional, and BUTI, Sebastiano, additional

Published
2023
Full Text
View/download PDF

33. Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9)

Author

Damassi, Alessandra, primary, Cremante, Malvina, additional, Signori, Alessio, additional, Rebuzzi, Sara Elena, additional, Fornarini, Giuseppe, additional, Giudice, Giulia Claire, additional, Maruzzo, Marco, additional, Procopio, Giuseppe, additional, Sorarù, Mariella, additional, Di Napoli, Marilena, additional, Fratino, Lucia, additional, Santini, Daniele, additional, Grillone, Francesco, additional, Ballestrin, Melissa, additional, Dionese, Michele, additional, Nasso, Cecilia, additional, Catalano, Fabio, additional, Murianni, Veronica, additional, Rescigno, Pasquale, additional, Anpalakhan, Shobana, additional, Banna, Giuseppe Luigi, additional, Basso, Umberto, additional, and Buti, Sebastiano, additional

Published
2023
Full Text
View/download PDF

34. Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis

Author

Messina, Carlo, primary, Giunta, Emilio Francesco, additional, Signori, Alessio, additional, Rebuzzi, Sara Elena, additional, Banna, Giuseppe Luigi, additional, Maniam, Akash, additional, Buti, Sebastiano, additional, Cattrini, Carlo, additional, Fornarini, Giuseppe, additional, Bauckneht, Matteo, additional, Greystoke, Alastair, additional, Plummer, Ruth, additional, Oing, Christoph, additional, and Rescigno, Pasquale, additional

Published
2023
Full Text
View/download PDF

35. Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score

Author

Mazzaschi, Giulia, primary, Lazzarin, Alessandro, primary, Santoni, Matteo, primary, Trentini, Francesca, primary, Giorgi, Ugo De, primary, Brighi, Nicole, primary, Tommasi, Chiara, primary, Puglisi, Silvia, primary, Caffo, Orazio, primary, Kinspergher, Stefania, primary, Mennitto, Alessia, primary, Cattrini, Carlo, primary, Verzoni, Elena, primary, Rametta, Alessandro, primary, Stellato, Marco, primary, Malgeri, Andrea, primary, Roviello, Giandomenico, primary, Silini, Enrico Maria, primary, Rescigno, Pasquale, primary, Rebuzzi, Sara Elena, primary, Fornarini, Giuseppe, primary, Quaini, Federico, primary, Giudice, Giulia Claire, primary, Banna, Giuseppe Luigi, primary, and Buti, Sebastiano, primary

Published
2023
Full Text
View/download PDF

36. Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?

Author

Santoni, Matteo, primary, Buti, Sebastiano, additional, Myint, Zin W., additional, Maruzzo, Marco, additional, Iacovelli, Roberto, additional, Pichler, Martin, additional, Kopecky, Jindrich, additional, Kucharz, Jakub, additional, Rizzo, Mimma, additional, Galli, Luca, additional, Büttner, Thomas, additional, De Giorgi, Ugo, additional, Kanesvaran, Ravindran, additional, Fiala, Ondřej, additional, Grande, Enrique, additional, Zucali, Paolo Andrea, additional, Kopp, Ray Manneh, additional, Fornarini, Giuseppe, additional, Bourlon, Maria T., additional, Scagliarini, Sarah, additional, Molina-Cerrillo, Javier, additional, Aurilio, Gaetano, additional, Matrana, Marc R., additional, Pichler, Renate, additional, Cattrini, Carlo, additional, Büchler, Tomas, additional, Massari, Francesco, additional, Seront, Emmanuel, additional, Calabrò, Fabio, additional, Pinto, Alvaro, additional, Berardi, Rossana, additional, Zgura, Anca, additional, Mammone, Giulia, additional, Ansari, Jawaher, additional, Atzori, Francesco, additional, Chiari, Rita, additional, Bamias, Aristotelis, additional, Caffo, Orazio, additional, Procopio, Giuseppe, additional, Sunela, Kaisa, additional, Bassanelli, Maria, additional, Ortega, Cinzia, additional, Grillone, Francesco, additional, Landmesser, Johannes, additional, Milella, Michele, additional, Messina, Carlo, additional, Küronya, Zsófia, additional, Mosca, Alessandra, additional, Bhuva, Dipen, additional, Santini, Daniele, additional, Vau, Nuno, additional, Morelli, Franco, additional, Incorvaia, Lorena, additional, Rebuzzi, Sara Elena, additional, Roviello, Giandomenico, additional, Soares, Andrey, additional, Bisonni, Renato, additional, Bimbatti, Davide, additional, Zabalza, Ignacio Ortego, additional, Rizzo, Alessandro, additional, Mollica, Veronica, additional, Sorgentoni, Giulia, additional, Monteiro, Fernando Sabino M., additional, Battelli, Nicola, additional, Bracarda, Sergio, additional, and Porta, Camillo, additional

Published
2023
Full Text
View/download PDF

37. Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study.

Author

Murianni, Veronica, Signori, Alessio, Buti, Sebastiano, Rebuzzi, Sara Elena, Bimbatti, Davide, De Giorgi, Ugo, Chiellino, Silvia, Galli, Luca, Zucali, Paolo Andrea, Masini, Cristina, Naglieri, Emanuele, Procopio, Giuseppe, Milella, Michele, Fratino, Lucia, and Baldessari, Cinzia

Subjects
RENAL cell carcinoma, IMMUNE checkpoint inhibitors, NIVOLUMAB, TREATMENT failure
Abstract

Background: Immunotherapies exhibit peculiar cancer response patterns in contrast to chemotherapy and targeted therapy. Some patients experience disease response after initial progression or durable responses after treatment interruption. In clinical practice, immune checkpoint inhibitors may be continued after radiological progression if clinical benefit is observed. As a result, estimating progression-free survival (PFS) based on the first disease progression may not accurately reflect the actual benefit of immunotherapy. Methods: The Meet-URO 15 study was a multicenter retrospective analysis of 571 pretreated metastatic renal cell carcinoma (mRCC) patients receiving nivolumab. Time to strategy failure (TSF) was defined as the interval from the start of immunotherapy to definitive disease progression or death. This posthoc analysis compared TSF to PFS and assess the response and survival outcomes between patients treatated beyond progression (TBP) and non- TBP. Moreover, we evaluated the prognostic accuracy of the Meet-URO score versus the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) score based on TSF and PFS. Results: Overall, 571 mRCC patients were included in the analysis. Median TSF was 8.6 months (95% CI: 7.0 - 10.1), while mPFS was 7.0 months (95% CI: 5.7 - 8.5). TBP patients (N = 93) had significantly longer TSF (16.3 vs 5.5 months; p < 0.001) and overall survival (OS) (34.8 vs 17.9 months; p < 0.001) but similar PFS compared to non-TBP patients. In TBP patients, a median delay of 9.6 months (range: 6.7-16.3) from the first to the definitive disease progression was observed, whereas non-TBP patients had overlapped median TSF and PFS (5.5 months). Moreover, TBP patients had a trend toward a higher overall response rate (33.3% vs 24.3%; p = 0.075) and disease control rate (61.3% vs 55.5%; p = 0.31). Finally, in the whole population the Meet-URO score outperformed the IMDC score in predicting both TSF (c-index: 0.63 vs 0.59) and PFS (0.62 vs 0.59). Conclusion: We found a 2-month difference between mTSF and mPFS in mRCC patients receiving nivolumab. However, TBP patients had better outcomes, including significantly longer TSF and OS than non-TBP patients. The Meet-URO score is a reliable predictor of TSF and PFS. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. Predicting efficacy in patients with locally advanced (LA)/metastatic urothelial carcinoma (mUC) treated with avelumab using machine learning and explainability approaches.

Author

Giannatempo, Patrizia, Miskovic, Vanja, Piceni, Matteo, Gambale, Elisabetta, Stellato, Marco, Bottiglieri, Achille, Walter, Ferrari Bravo, Oldani, Simone, Maruzzo, Marco, Bimbatti, Davide, Mennitto, Alessia, Rebuzzi, Sara Elena, Mercinelli, Chiara, Sorarù, Mariella, Galli, Luca, Messina, Carlo, Iacovelli, Roberto, Antonuzzo, Lorenzo, Prelaj, Arsela, and Procopio, Giuseppe

Published
2024
Full Text
View/download PDF

40. Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study

Author

Rebuzzi, Sara Elena, primary, Brunelli, Matteo, additional, Galuppini, Francesca, additional, Vellone, Valerio Gaetano, additional, Signori, Alessio, additional, Catalano, Fabio, additional, Damassi, Alessandra, additional, Gaggero, Gabriele, additional, Rescigno, Pasquale, additional, Maruzzo, Marco, additional, Merler, Sara, additional, Vignani, Francesca, additional, Cavo, Alessia, additional, Basso, Umberto, additional, Milella, Michele, additional, Panepinto, Olimpia, additional, Mencoboni, Manlio, additional, Sbaraglia, Marta, additional, Dei Tos, Angelo Paolo, additional, Murianni, Veronica, additional, Cremante, Malvina, additional, Llaja Obispo, Miguel Angel, additional, Maffezzoli, Michele, additional, Banna, Giuseppe Luigi, additional, Buti, Sebastiano, additional, and Fornarini, Giuseppe, additional

Published
2023
Full Text
View/download PDF

41. Safety of Extended interval Dosing Immune Checkpoint Inhibitors: a multicentre cohort study

Author

Cantini, Luca, primary, Paoloni, Francesco, additional, Pecci, Federica, additional, Spagnolo, Francesco, additional, Genova, Carlo, additional, Tanda, Enrica Teresa, additional, Aerts, Sophie, additional, Rebuzzi, Sara Elena, additional, Fornarini, Giuseppe, additional, Zoratto, Federica, additional, Fancelli, Sara, additional, Lupi, Alessio, additional, Della Corte, Carminia Maria, additional, Parisi, Alessandro, additional, Bennati, Chiara, additional, Ortega, Cinzia, additional, Atzori, Francesco, additional, Piovano, Pier Luigi, additional, Orciuolo, Corrado, additional, De Tursi, Michele, additional, Ghidini, Michele, additional, Botticelli, Andrea, additional, Scagnoli, Simone, additional, Belluomini, Lorenzo, additional, Leporati, Rita, additional, Veccia, Antonello, additional, Di Giacomo, Anna Maria, additional, Festino, Lucia, additional, Cortinovis, Diego, additional, Acquati, Mirko, additional, Filetti, Marco, additional, Giusti, Raffaele, additional, Tucci, Marco, additional, Sergi, Maria Chiara, additional, Garutti, Mattia, additional, Puglisi, Fabio, additional, Manglaviti, Sara, additional, Citarella, Fabrizio, additional, Santoni, Matteo, additional, Rijavec, Erika, additional, Lo Russo, Giuseppe, additional, Santini, Daniele, additional, Addeo, Alfredo, additional, Antonuzzo, Lorenzo, additional, Indini, Alice, additional, Rocchi, Marco Bruno Luigi, additional, Cortellini, Alessio, additional, Grossi, Francesco, additional, Ascierto, Paolo Antonio, additional, Aerts, Joachim G J V, additional, and Berardi, Rossana, additional

Published
2023
Full Text
View/download PDF

42. Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome?

Author

Corianò, Matilde, primary, Giannarelli, Diana, additional, Scartabellati, Giulia, additional, De Giorgi, Ugo, additional, Brighi, Nicole, additional, Fornarini, Giuseppe, additional, Tommasi, Chiara, additional, Giudice, Giulia Claire, additional, Rebuzzi, Sara Elena, additional, Puglisi, Silvia, additional, Caffo, Orazio, additional, Kinspergher, Stefania, additional, Mennitto, Alessia, additional, Cattrini, Carlo, additional, Santoni, Matteo, additional, Verzoni, Elena, additional, Rametta, Alessandro, additional, Stellato, Marco, additional, Malgeri, Andrea, additional, Roviello, Giandomenico, additional, Brunelli, Matteo, additional, Signori, Alessio, additional, Banna, Giuseppe Luigi, additional, and Buti, Sebastiano, additional

Published
2023
Full Text
View/download PDF

43. The DASciS Software for BSI Calculation as a Valuable Prognostic Tool in mCRPC Treated with 223RaCl2: A Multicenter Italian Study

Author

De Feo, Maria Silvia, primary, Frantellizzi, Viviana, additional, Bauckneht, Matteo, additional, Farcomeni, Alessio, additional, Filippi, Luca, additional, Rizzini, Elisa Lodi, additional, Lavelli, Valentina, additional, Stazza, Maria Lina, additional, Di Raimondo, Tania, additional, Fornarini, Giuseppe, additional, Rebuzzi, Sara Elena, additional, Filippo, Mammini, additional, Mammucci, Paolo, additional, Marongiu, Andrea, additional, Monari, Fabio, additional, Rubini, Giuseppe, additional, Spanu, Angela, additional, and De Vincentis, Giuseppe, additional

Published
2023
Full Text
View/download PDF

44. Safety of extended interval dosing immune checkpoint inhibitors:a multicenter cohort study

Author

Cantini, Luca, Paoloni, Francesco, Pecci, Federica, Spagnolo, Francesco, Genova, Carlo, Tanda, Enrica Teresa, Aerts, Sophie, Rebuzzi, Sara Elena, Fornarini, Giuseppe, Zoratto, Federica, Fancelli, Sara, Lupi, Alessio, Della Corte, Carminia Maria, Parisi, Alessandro, Bennati, Chiara, Ortega, Cinzia, Atzori, Francesco, Piovano, Pier Luigi, Orciuolo, Corrado, De Tursi, Michele, Ghidini, Michele, Botticelli, Andrea, Scagnoli, Simone, Belluomini, Lorenzo, Leporati, Rita, Veccia, Antonello, Di Giacomo, Anna Maria, Festino, Lucia, Cortinovis, Diego, Acquati, Mirko, Filetti, Marco, Giusti, Raffaele, Tucci, Marco, Sergi, Maria Chiara, Garutti, Mattia, Puglisi, Fabio, Manglaviti, Sara, Citarella, Fabrizio, Santoni, Matteo, Rijavec, Erika, Lo Russo, Giuseppe, Santini, Daniele, Addeo, Alfredo, Antonuzzo, Lorenzo, Indini, Alice, Rocchi, Marco Bruno Luigi, Cortellini, Alessio, Grossi, Francesco, Ascierto, Paolo Antonio, Aerts, Joachim G.J.V., Berardi, Rossana, Cantini, Luca, Paoloni, Francesco, Pecci, Federica, Spagnolo, Francesco, Genova, Carlo, Tanda, Enrica Teresa, Aerts, Sophie, Rebuzzi, Sara Elena, Fornarini, Giuseppe, Zoratto, Federica, Fancelli, Sara, Lupi, Alessio, Della Corte, Carminia Maria, Parisi, Alessandro, Bennati, Chiara, Ortega, Cinzia, Atzori, Francesco, Piovano, Pier Luigi, Orciuolo, Corrado, De Tursi, Michele, Ghidini, Michele, Botticelli, Andrea, Scagnoli, Simone, Belluomini, Lorenzo, Leporati, Rita, Veccia, Antonello, Di Giacomo, Anna Maria, Festino, Lucia, Cortinovis, Diego, Acquati, Mirko, Filetti, Marco, Giusti, Raffaele, Tucci, Marco, Sergi, Maria Chiara, Garutti, Mattia, Puglisi, Fabio, Manglaviti, Sara, Citarella, Fabrizio, Santoni, Matteo, Rijavec, Erika, Lo Russo, Giuseppe, Santini, Daniele, Addeo, Alfredo, Antonuzzo, Lorenzo, Indini, Alice, Rocchi, Marco Bruno Luigi, Cortellini, Alessio, Grossi, Francesco, Ascierto, Paolo Antonio, Aerts, Joachim G.J.V., and Berardi, Rossana

Abstract

BACKGROUND: Real-life spectrum and survival implications of immune-related adverse events (irAEs) in patients treated with extended interval dosing (ED) immune checkpoint inhibitors (ICIs) are unknown. METHODS: Characteristics of 812 consecutive solid cancer patients who received at least 1 cycle of ED monotherapy (pembrolizumab 400 mg Q6W or nivolumab 480 mg Q4W) after switching from canonical interval dosing (CD; pembrolizumab 200 mg Q3W or nivolumab 240 mg Q2W) or treated upfront with ED were retrieved. The primary objective was to compare irAEs patterns within the same population (before and after switch to ED). irAEs spectrum in patients treated upfront with ED and association between irAEs and overall survival were also described. RESULTS: A total of 550 (68%) patients started ICIs with CD and switched to ED. During CD, 225 (41%) patients developed any grade and 17 (3%) G3 or G4 irAEs; after switching to ED, any grade and G3 or G4 irAEs were experienced by 155 (36%) and 20 (5%) patients. Switching to ED was associated with a lower probability of any grade irAEs (adjusted odds ratio [aOR] = 0.83, 95% confidence interval [CI] = 0.64 to 0.99; P = .047), whereas no difference for G3 or G4 events was noted (aOR = 1.55, 95% CI = 0.81 to 2.94; P = .18). Among patients who started upfront with ED (n = 232, 32%), 107 (41%) developed any grade and 14 (5%) G3 or G4 irAEs during ED. Patients with irAEs during ED had improved overall survival (adjusted hazard ratio [aHR] = 0.53, 95% CI = 0.34 to 0.82; P = .004 after switching; aHR = 0.57, 95% CI = 0.35 to 0.93; P = .025 upfront). CONCLUSIONS: Switching ICI treatment from CD and ED did not increase the incidence of irAEs and represents a safe option also outside clinical trials.

Published
2023

46. Apalutamide-induced lichenoid reaction in a patient with non-metastatic castrate-resistant prostate cancer.

Author

Cremante, Malvina, Puglisi, Silvia, Gandini, Annalice, Guadagno, Antonio, Catalano, Fabio, Damassi, Alessandra, Murianni, Veronica, Llaja Obispo, Miguel Angel, Banna, Giuseppe Luigi, Buti, Sebastiano, Rebuzzi, Sara Elena, Rescigno, Pasquale, and Fornarini, Giuseppe

Subjects
SKIN disease diagnosis, SKIN diseases, ANTIANDROGENS, PROFESSIONS, CASTRATION-resistant prostate cancer, HEALTH care teams, DRUG eruptions
Abstract

Introduction: Apalutamide is an oral selective androgen receptor inhibitor, approved by the FDA for the treatment of patients with non-metastatic, castration-resistant prostate cancer (M0 CRPC) at high risk of developing metastases and for patients with metastatic castration-sensitive prostate (mHSPC) in association with androgen deprivation therapy (ADT). In the registration studies, skin reactions were reported among the most common side effects and as an adverse event of special interest. Case Report: Apalutamide-induced rash includes a wide spectrum of different types of skin reactions, but few cases reports and case series have described this adverse event. Here, we report an M0 CRPC patient who experienced a rare skin adverse event, a lichenoid reaction. Management & Outcome: After 4 months of therapy with apalutamide, the patient reported dorsal pricking and dry skin. Lichenoid reaction was confirmed histologically and its correlation to the drug was demonstrated after pursuing a multidisciplinary approach. Discussion: To our knowledge, this is one of the first cases of Apalutamide-related lichenoid reaction and this clinical case showed the relevance of a multidisciplinary management when assessing drug-related adverse events. A broader knowledge of the spectrum of drug-related reactions would allow for a better diagnosis and therapy management by both physicians and patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

47. Correlation of the immune tumor microenvironment (I-TME) with gene expression profiles as prognostic and predictive factors in patients (pts) with metastatic renal carcinoma (mRCC) treated with immunotherapy (Meet-URO 18 I-TME study).

Author

Catalano, Fabio, primary, Murianni, Veronica, additional, Rebuzzi, Sara Elena, additional, Galuppini, Francesca, additional, Buti, Sebastiano, additional, Brunelli, Matteo, additional, Maruzzo, Marco, additional, Dei Tos, Angelo Paolo, additional, Basso, Umberto, additional, Banna, Giuseppe Lugi, additional, Signori, Alessio, additional, Sbaraglia, Marta, additional, Damassi, Alessandra, additional, Cremante, Malvina, additional, Puglisi, Silvia, additional, Gandini, Annalice, additional, Rebuzzi, Marta, additional, Mosca, Alessandra, additional, Fornarini, Giuseppe, additional, and Rescigno, Pasquale, additional

Published
2023
Full Text
View/download PDF

48. Prognostic stratification by the Meet-URO score in a real-world elderly population of patients (pts) with metastatic renal cell carcinoma (mRCC) receiving cabozantinib: A subanalysis of the prospective ZEBRA study (Meet-URO 9).

Author

Damassi, Alessandra, primary, Cremante, Malvina, additional, Fornarini, Giuseppe, additional, Signori, Alessio, additional, Buti, Sebastiano, additional, Basso, Umberto, additional, Procopio, Giuseppe, additional, Maruzzo, Marco, additional, Sorarù, Mariella, additional, Di Napoli, Marilena, additional, Fratino, Lucia, additional, Santini, Daniele, additional, Grillone, Francesco, additional, Ballestrin, Melissa, additional, Dionese, Michele, additional, Murianni, Veronica, additional, Catalano, Fabio, additional, Banna, Giuseppe Luigi L., additional, Rescigno, Pasquale, additional, and Rebuzzi, Sara Elena, additional

Published
2023
Full Text
View/download PDF

49. Outcomes of post-progression therapies in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) progressing after docetaxel (DOC): Real-world data from an Italian multicenter observational study (ECHOS trial).

Author

Caffo, Orazio, primary, Maruzzo, Marco, additional, Samuelly, Alessandro, additional, Facchini, Gaetano, additional, Zanardi, Elisa, additional, Nicodemo, Maurizio, additional, Ermacora, Paola, additional, Sorarù, Mariella, additional, Galli, Luca, additional, Cattrini, Carlo, additional, Borsellino, Nicolo, additional, Buti, Sebastiano, additional, Rebuzzi, Sara Elena, additional, Iacovelli, Roberto, additional, Rametta, Alessandro, additional, Calvani, Nicola, additional, Giordano, Monica, additional, Farnesi, Azzurra, additional, Fratino, Lucia, additional, and Basso, Umberto, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results